MDxHealth is a multinational healthcare company that provides actionable epigenetic information to personalize the diagnosis and treatment of cancer. The company's tests are based on proprietary gene methylation (epigenetic) technology and assist physicians with the diagnosis of cancer, prognosis of recurrence risk, and prediction of response to a specific therapy.
NovioGendix has focused on developing the “liquid biopsy,” an mRNA-based test designed to help differentiate patients with aggressive, clinically significant prostate cancer, from those with slower growing cancer. According to the company, initial comparative studies have shown the new mRNA test outperforms the prostate cancer antigen 3 (PCA3) gene test in clinical performance.
MDxHealth said it will continue the scientific collaboration between NovioGendix and the Radboud University Medical Center in Nijmegen, the Netherlands, where the PCA3 test was discovered. In addition to SelectMDx, NovioGendix has a range of diagnostic tests for prostate, bladder, kidney, and other urologic cancers in various stages of development.
Dr. Jan Groen, Chief Executive Officer of MDxHealth, commented: "Our focus is to build MDxHealth into a market leader in molecular diagnostics for uro-oncology. The acquisition of NovioGendix provides us with a validated, non-invasive, actionable testing option for prostate cancer and allows us to address the larger market opportunity of initial prostate biopsy for early cancer detection.
Dr. Willem Melchers, Chief Executive Officer of NovioGendix, commented: "MDxHealth is the optimum strategic fit to ensure that NovioGendix's unique, non-invasive prostate cancer test is successfully commercialized internationally. We are very excited to be working with the MDxHealth team to continue our commitment to delivering high quality molecular tests that improve the medical care of urological cancer patients around the world".
The completion of the acquisition is contemplated to occur on or about September 18, 2015.